Last reviewed · How we verify
NCT02669771
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
trial testing enzalutamide in Castration-resistant Prostate Cancer in 1,018 participants. Completed in 30 November 2018.
30 November 2018
Quick facts
| Lead sponsor | Astellas Pharma Inc |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,018 |
| Start date | 30 November 2014 |
| Primary completion | 30 November 2018 |
| Estimated completion | 30 November 2018 |
| Sites | 47 locations across Japan |
Drugs / interventions tested
- enzalutamide (enzalutamide) — full drug profile →
Conditions studied
- Castration-resistant Prostate Cancer — all drugs for Castration-resistant Prostate Cancer →
Sponsor
Astellas Pharma Inc — full company profile →
Who can join
Eligibility, male only, with Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02669771
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of enzalutamide
Trials testing the same drug.
- NCT06257693 — Enzalutamide Implants (Enolen) in Patients With Prostate Cancer · Phase 1 · recruiting
- NCT06702995 — Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cance · Phase 1, PHASE2 · recruiting
- NCT05701007 — Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland · completed
- NCT05457257 — Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Pr · Phase 4 · completed
- NCT04729114 — A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer · Phase 1 · recruiting
Other recruiting trials for Castration-resistant Prostate Cancer
Currently open trials in the same condition.
- NCT07259213 — A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC · Phase 1, PHASE2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT06636123 — GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy · Phase 1 · recruiting
- NCT06378866 — Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati · Phase 2 · recruiting
- NCT06585007 — Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer · Phase 3 · recruiting
Other Astellas Pharma Inc trials
Trials by the same sponsor.
- NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
- NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
- NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02669771 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02669771.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing